What's in Immatics US, Inc.'s pipeline?

Immatics US, Inc. has 10 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 7 in Phase 1.

Which companies overlap with Immatics US, Inc.'s portfolio?

Top competitors by shared drug class: Amgen, Anhui Shi, MD, Arrevus Inc., AstraZeneca, Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/immatics-us-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Immatics US, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immatics US, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
IMA203	IMA203	phase 3	Bispecific T-cell engager (BiTE)	CD3 and PRAME	Oncology
nivolumab plus relatlimab	nivolumab plus relatlimab	phase 3	PD-1/PD-L1 inhibitor	PD-1, LAG-3	Oncology
paclitaxel plus carboplatin	paclitaxel plus carboplatin	phase 3	Taxane and platinum-based chemotherapy		Oncology

Therapeutic area mix

Oncology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
Anhui Shi, MD · 1 shared drug class
Arrevus Inc. · 1 shared drug class
AstraZeneca · 1 shared drug class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
Cellvax Therapeutics Inc · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Akeso · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Immatics US, Inc.:

Cite this brief

Drug Landscape (2026). Immatics US, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/immatics-us-inc. Accessed 2026-06-10.